Satellos Bioscience(MSLE.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Satellos Bioscience
MSLE.US
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia.
2.004 T
MSLE.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Satellos to Host February 24 Virtual KOL Event Showcasing SAT-3247 in Duchenne Muscular Dystrophy

    Tip Ranks·
    US
    TBIO
    0.00%
    US
    XBI
    -0.23%
    US
    IBB
    +0.86%
    Tip Ranks·
    US
    TBIO
    0.00%
    US
    XBI
    -0.23%
    US
    IBB
    +0.86%

    Stocks in Play: Satellos Bioscience Inc.

    Baystreet·
    US
    IBB
    +0.86%
    US
    SBIO
    -0.97%
    US
    ASMB
    +0.84%
    Baystreet·
    US
    IBB
    +0.86%
    US
    SBIO
    -0.97%
    US
    ASMB
    +0.84%

    Satellos Bioscience to Join Guggenheim Securities Emerging Outlook Biotech Summit

    Reuters·
    US
    BBH
    +1.77%
    US
    PBE
    +0.78%
    US
    IBB
    +0.86%
    Reuters·
    US
    BBH
    +1.77%
    US
    PBE
    +0.78%
    US
    IBB
    +0.86%

    Satellos Bioscience gibt Ausgabe von Optionsscheinen und Aktien bekannt

    Reuters·
    US
    IBB
    +0.86%
    US
    BBH
    +1.77%
    US
    PBE
    +0.78%
    Reuters·
    US
    IBB
    +0.86%
    US
    BBH
    +1.77%
    US
    PBE
    +0.78%

    Satellos Bioscience Raises $57.2 Million Through Share and Pre-Funded Warrant Offering

    Reuters·
    US
    BIB
    +1.74%
    US
    XBI
    -0.23%
    US
    IBB
    +0.86%
    Reuters·
    US
    BIB
    +1.74%
    US
    XBI
    -0.23%
    US
    IBB
    +0.86%
    © 2026 Longbridge｜Disclaimer